Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
arcticnovartis
Wed, 11/27/2024 – 07:19
Read more about Novartis Kisqali® receives European Comm…
Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS
arcticnovartis
Mon, 11/25/2024 – 07:19
Read more about Novartis highlights new 96-wee…
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
arcticnovartis
Thu, 11/21/2024 – 07:04
Read more about Novartis upgrades mid-term guidance and highlights deep pipeline in core th…
Novartis ranks first in 2024 Access to Medicine Index
arcticnovartis
Tue, 11/19/2024 – 14:04
Read more about Novartis ranks first in 2024 Access to Medicine Index
The Index spotlights Novartis leadership in research and development…
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
arcticnovartis
Tue, 10/29/2024 – 20:14
Read more about Novartis Scemblix® FDA approved in newly diagnosed CML, offeri…
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
arcticnovartis
Tue, 10/29/2024 – 20:14
Read more about Novartis Scemblix® FDA approved in newly diagnosed CML, offeri…
Novartis setzt die starke Dynamik im dritten Quartal fort mit Steigerungen beim Umsatz (+10%) und operativen Kernergebnis (+20%) sowie wichtigen Innovationsmeilensteinen; Prognose für 2024 angehoben
arcticnovartis
Tue, 10/29/2024 – 07:02
Read more…
Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance
arcticnovartis
Tue, 10/29/2024 – 07:02
Read more about Novartis continues strong momentu…
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
arcticnovartis
Sun, 10/27/2024 – 02:04
Read more about Novartis oral Fabhalta® (iptacopan) sustained clinicall…
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
arcticnovartis
Sun, 10/27/2024 – 02:04
Read more about Novartis oral Fabhalta® (iptacopan) sustained clinicall…